Form 4: Boston Scientific Executive Vance R. Brown Reports Stock Transactions

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On February 12, 2025, Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reported transactions involving Boston Scientific common stock and restricted stock units.
• Brown acquired 1,442 shares of common stock upon the vesting of restricted stock units.
• Brown disposed of 424 shares of common stock to cover tax obligations at a price of $105.77 per share.
• Following these transactions, Brown directly owns 48,251 shares of Boston Scientific common stock.
• Brown also directly owns 4,328 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by a company executive, and does not contain any information that would significantly impact investor sentiment positively or negatively.

Future Outlook

The remaining restricted stock units will vest in four equal annual installments beginning on February 12, 2025.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) as a way to align management's interests with those of shareholders.
• The vesting schedule of these RSUs, such as the four-year vesting period described in the document, is a common practice in the industry.
• Companies like Medtronic, Abbott, and Johnson & Johnson also utilize RSUs as part of their executive compensation plans.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine stock transactions by an executive.
• The disclosure provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, Boston Scientific, BSX, Vance R. Brown, Stock Transaction, Restricted Stock Units, Beneficial Ownership, SEC Filing